Evidence digest
The indexed literature on Melanotan II includes human clinical or observational records (5 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Melanotan II is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 5 studies indexed · 5 human · compound record
Origin Labs1 Melanotan II certificate96.9of 100Extensively documentedVisit Origin Labs
Next Gen Peptides$2.50/mg listed · 3 Melanotan II certificates93.6of 100Extensively documentedVisit Next Gen Peptides
Amino Club$3.00/mg listed · 2 Melanotan II certificates90.5of 100Extensively documentedVisit Amino ClubRanked on this compound's price per mg against the market median, with testing and documentation counted as they are overall. What a vial contains is answered by that vendor's certificates, not by the studies below.
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Published reports concerning melanotan II obtained outside licensed supplyPubMed listing | Case report | Not recorded | — | The listed literature includes case reports concerning material obtained outside a licensed medical context. Case reports describe individual occurrences and cannot establish incidence, causation or population-level risk. | Listing |
| Melanotan-induced priapism: a hard-earned tanBMJ case reports · 2019 | Case report | Not recorded | — | Melanocortin analogues, such as melanotan, are illegally used for artificial tanning. They have also been suggested as possible therapeutic agents in the treatment of erectile dysfunction. This case study presents a patient attending the accident and emergency department, in a tertiary urology centre, with acute priapism after abdominal subcutaneous injection of melanotan. The priapism was diagnosed as 'low-flow' and managed with cavernosal aspiration, irrigation and subseque… | PMID 30796078 |
| Melanotan-associated melanomaThe British journal of dermatology · 2011 | Case report | Not recorded | — | A case report published in The British journal of dermatology (2011). Reported outcomes are described in the linked publication; PepIndex does not summarise clinical significance. | PMID 21564053 |
| Melanotan II: a possible cause of renal infarction: review of the literature and case reportCEN case reports · 2020 | Case report | Not recorded | — | Renal infarction is an uncommon condition resulting from an acute disruption of renal blood flow and it is potentially life-threatening disease. The cause and outcome of renal infarction is not well established and is frequently misdiagnosed or diagnosed late. Melanotan II is a non-selective melanocortin-receptor agonist and its effect on humans is an increasing of skin pigmentation, producing of spontaneous penile erection and sexual stimulation. Melanotan II inducing rhabdo… | PMID 31953620 |
| A glimpse into the underground market of melanotanDermatology online journal · 2018 | Human — observational | Not recorded | — | Melanotan-I and melanotan-II are alpha-melanocyte stimulating hormone (a-MSH) analogues that can be purchased illicitly online with relative ease and are injected subcutaneously to stimulate a tan. Little is known about the use of these unregulated substances. An observational survey was posted to an online forum in which participants share their experiences using melanotan-I or melanotan-II. Users were asked to complete this voluntary, anonymous survey, which had questions f… | PMID 30142729 |
The UK regulator has published guidance and enforcement positions on the supply of unlicensed medicines to the public, including substances marketed as research chemicals. Several compounds tracked here have been the subject of public statements. PepIndex records those affecting indexed compounds.
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Origin Labs | 96.9100% | 1 | Visit |
| Next Gen Peptides | 93.697% | 3 | Visit |
| Amino Club | 90.598% | 2 | Visit |
 Ascend Science | 88.994% | 0 | Visit |
 PeptidePlugs | 87.694% | 2 | Visit |
 Hydro Research Peptides | 83.989% | 1 | Visit |
 One Aminos | 82.789% | 1 | Visit |
 Stealth Research Labs | 82.191% | 1 | Visit |
 Modern Aminos | 81.197% | 0 | Visit |
 Bench Grade Peptides | 80.789% | 1 | Visit |
 Simple Peptide | 79.192% | 1 | Visit |
 NeuroLabs Research | 7991% | 1 | Visit |
 Ascension Peptides | 78.989% | 0 | Visit |
 Koi Peptides | 76.492% | 0 | Visit |
 Prime Peptides | 75.796% | 0 | Visit |
 Protide Health | 73.792% | 0 | Visit |
 Evo Labs Research | 73.387% | 0 | Visit |
| NLNorthline Labs | 7195% | 1 | Visit |
| GSGood Science Bio | 70.871% | 0 | Visit |
| EPEternal Peptides | 67.963% | 0 | Visit |
| GPGenX Peptides | 64.969% | 0 | Visit |
| TRTrue Research Labs | 6468% | 0 | Visit |
| LPLicensed Peptides | 61.487% | 0 | Visit |
| MHMile High Compounds | 60.591% | 0 | Visit |
| VDVial Drop Labs | 59.474% | 1 | Visit |
| IPImproved Peptides | 59.187% | 0 | Visit |
| EPExtreme Peptides | 57.980% | 0 | Visit |
| VLVertex Labs | 56.172% | 1 | Visit |
| PPeptime | 55.557% | 1 | Visit |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.